Medtronic PLC $MDT Stock Position Lifted by Cahill Financial Advisors Inc.

Cahill Financial Advisors Inc. grew its position in Medtronic PLC (NYSE:MDT) by 133.0% in the second quarter, Holdings Channel.com reports. The fund owned 13,776 shares of the medical technology company’s stock after buying an additional 7,864 shares during the period. Cahill Financial Advisors Inc.’s holdings in Medtronic were worth $1,201,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. 1248 Management LLC acquired a new position in Medtronic in the first quarter worth $26,000. Twin Tree Management LP bought a new position in shares of Medtronic in the 1st quarter worth about $29,000. Activest Wealth Management lifted its position in shares of Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after buying an additional 322 shares during the last quarter. Hughes Financial Services LLC acquired a new position in shares of Medtronic in the 1st quarter valued at about $32,000. Finally, Investment Management Corp VA ADV grew its position in shares of Medtronic by 144.2% during the 1st quarter. Investment Management Corp VA ADV now owns 403 shares of the medical technology company’s stock valued at $36,000 after buying an additional 238 shares during the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Citigroup increased their price objective on shares of Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Robert W. Baird increased their price target on Medtronic from $94.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 20th. UBS Group raised their price target on Medtronic from $94.00 to $95.00 and gave the stock a “neutral” rating in a report on Wednesday, August 20th. Needham & Company LLC restated a “hold” rating on shares of Medtronic in a research report on Thursday, August 14th. Finally, Daiwa Capital Markets upped their price objective on Medtronic from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $102.82.

Medtronic Stock Up 2.4%

Medtronic stock opened at $92.22 on Monday. The company’s 50-day moving average price is $94.20 and its two-hundred day moving average price is $90.05. The stock has a market cap of $118.29 billion, a price-to-earnings ratio of 25.41, a PEG ratio of 2.42 and a beta of 0.77. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $99.37. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business had revenue of $8.58 billion during the quarter, compared to analysts’ expectations of $8.37 billion. During the same period last year, the firm posted $1.23 earnings per share. The business’s revenue was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 17th. Stockholders of record on Friday, September 26th were given a dividend of $0.71 per share. The ex-dividend date was Friday, September 26th. This represents a $2.84 annualized dividend and a dividend yield of 3.1%. Medtronic’s dividend payout ratio (DPR) is 78.24%.

Insiders Place Their Bets

In other news, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the sale, the executive vice president owned 35,615 shares in the company, valued at $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director William R. Jellison bought 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The shares were purchased at an average cost of $92.37 per share, with a total value of $230,925.00. Following the purchase, the director directly owned 5,000 shares of the company’s stock, valued at approximately $461,850. This represents a 100.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.26% of the stock is currently owned by insiders.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.